Cerity Partners LLC Purchases Shares of 59,623 bluebird bio, Inc. (NASDAQ:BLUE)

Cerity Partners LLC acquired a new position in shares of bluebird bio, Inc. (NASDAQ:BLUE) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 59,623 shares of the biotechnology company’s stock, valued at approximately $82,000. Cerity Partners LLC owned about 0.05% of bluebird bio at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Aigen Investment Management LP bought a new stake in bluebird bio during the 3rd quarter worth approximately $34,000. Sequoia Financial Advisors LLC acquired a new position in bluebird bio in the fourth quarter worth $37,000. Johnson Investment Counsel Inc. bought a new stake in shares of bluebird bio during the third quarter worth $40,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in shares of bluebird bio by 6.5% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 77,996 shares of the biotechnology company’s stock valued at $237,000 after buying an additional 4,751 shares in the last quarter. Finally, New York State Common Retirement Fund raised its holdings in shares of bluebird bio by 17.0% in the third quarter. New York State Common Retirement Fund now owns 114,195 shares of the biotechnology company’s stock valued at $347,000 after buying an additional 16,603 shares during the last quarter. Institutional investors and hedge funds own 87.43% of the company’s stock.

bluebird bio Trading Down 3.9 %

NASDAQ BLUE opened at $0.89 on Wednesday. bluebird bio, Inc. has a 12 month low of $0.86 and a 12 month high of $5.53. The stock has a 50-day simple moving average of $1.25 and a 200 day simple moving average of $1.94. The company has a market capitalization of $97.00 million, a PE ratio of -1.20 and a beta of 0.74.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on BLUE shares. HSBC decreased their price objective on shares of bluebird bio from $2.31 to $1.02 and set a “reduce” rating on the stock in a report on Tuesday, March 5th. Wells Fargo & Company decreased their price target on shares of bluebird bio from $4.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Wednesday, March 27th. StockNews.com upgraded shares of bluebird bio to a “sell” rating in a research report on Thursday, March 28th. William Blair reiterated a “market perform” rating on shares of bluebird bio in a research report on Tuesday, January 9th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $6.00 target price on shares of bluebird bio in a research note on Wednesday, March 27th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $5.74.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.